PacBio

270 articles about PacBio

• MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant to empower non-model organism research

  11/21/2023

  MedGenome, a global partner for comprehensive multiomics solutions, is pleased to announce a grant for De Novo Genome Assembly and Annotation, in collaboration with PacBio, a pioneer in long-read sequencing.

• PacBio to Present at Upcoming November 2023 Investor Conferences

  11/9/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

  11/2/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the creation of the HiFi Solves consortium.

• PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible

  11/1/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the addition of two tertiary analysis partners to PacBio Compatible.

• PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications

  10/31/2023

  PacBio (NASDAQ: PACB) today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing on PacBio's long-read sequencing systems to enable large-scale studies at a resolution difficult to attain with short-read RNA sequencing.

• PacBio Announces Third Quarter 2023 Financial Results

  10/30/2023

  PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023.

• PacBio Announces Appointment of David Meline to Board of Directors

  10/16/2023

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023.

• PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

  10/11/2023

  PacBio today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis.

• PacBio Announces Collaboration with Leading Library Preparation Automation Partners

  9/7/2023

  PacBio today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

• PacBio to Present at Upcoming Investor Conferences - August 09, 2023

  8/9/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

  8/7/2023

  PacBio and GeneDx today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

• PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)

  8/5/2023

  PacBio announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units covering 184,700 shares of PacBio common stock to fourteen non-executive employees.

• PacBio Announces Second Quarter 2023 Financial Results

  8/2/2023

  PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023.

• PacBio Begins Commercialization of the Onso Short-Read Sequencing System

  8/2/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence.

• PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023

  7/19/2023

  PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 5:00 pm Eastern Time.

• Sampled Named a Certified Service Provider for PacBio

  7/11/2023

  Sampled today announced that it has been named a Certified Service Provider for PacBio, a leading developer of high-quality, highly accurate sequencing solutions, equipping Sampled to deliver the highest quality advanced sequencing technology services on PacBio’s technology.

• PacBio's Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease

  6/28/2023

  PacBio today announced that Bioscientia  is using its Revio long-read sequencing systems to expand its genomics research projects and sequence several thousand human genomes per year.

• PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030

  6/26/2023

  PacBio announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 in exchange for $441 million principal amount of the 2028 Notes, in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.

• PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research

  6/14/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions announced a clinical research study with Radboud University Medical Center to explore genetic causes of rare and genetic diseases.

• PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board

  5/30/2023

  PacBio announced the appointment of Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board and Jay Shendure, Ph.D. as Chair.